• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Oscar Health Announces Results for Third Quarter 2023 and Raises Full Year 2023 Adjusted EBITDA Outlook; New +Oscar Agreement

    11/7/23 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email
    • For the quarter ended September 30, 2023:
      • Direct and Assumed Policy Premiums of $1.6 billion, a 5% decrease YoY
      • Premiums earned of $1.4 billion, a 46% increase YoY
      • Medical Loss Ratio of 83.8%, a 608 bps improvement YoY
      • Net loss of $65.7 million, an improvement of $127.8 million YoY
      • Adjusted EBITDA loss of $20.3 million, an improvement of $139.5 million YoY
      • InsuranceCo Administrative Expense Ratio of 17.4%, a 326 bps improvement YoY
      • InsuranceCo Combined Ratio of 101.3%, a 934 bps improvement YoY
      • Adjusted Administrative Expense Ratio of 20.3%, a 443 bps improvement YoY

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results for the third quarter ended September 30, 2023.

    "Oscar reported strong third quarter results with significant year-over-year improvement across all core ratios," said Mark Bertolini, CEO of Oscar. "We are pleased with our year-to-date outperformance and are raising our full year outlook for 2023 InsuranceCo Adjusted EBITDA and consolidated Adjusted EBITDA. We are well-positioned to deliver $155 million to $165 million of profit in our insurance business in 2023 and to achieve Total Company Adjusted EBITDA profitability in 2024."

    Total Direct and Assumed Policy Premiums were $1.6 billion in the quarter, down 5% year-over-year ("YoY"), driven primarily by lower membership, partially offset by rate increases. Premiums earned in the quarter were up 46% YoY, driven primarily by the impact of deposit accounting for quota share reinsurance agreements, and lower risk transfer per member as a percent of premiums.

    Oscar's InsuranceCo Combined Ratio, which is the sum of its Medical Loss Ratio ("MLR") and the InsuranceCo Administrative Expense Ratio, improved 934 bps YoY to 101.3%, driven by both an improved MLR and administrative cost efficiencies. Specifically, the MLR improved 608 bps YoY to 83.8%, due to targeted rate increases and a disciplined pricing strategy, and total cost of care initiatives. The InsuranceCo Administrative Expense Ratio improved 326 bps YoY to 17.4%, due to higher net premiums as a result of lower risk transfer per member as a percent of premiums, variable expense efficiencies, and lower distribution expenses.

    The Adjusted Administrative Expense Ratio improved 443 bps YoY to 20.3%, driven primarily by higher net premiums as a result of lower risk transfer per member as a percent of premiums, higher net investment income, and variable expense efficiencies. Adjusted EBITDA loss of $20.3 million significantly improved by $139.5 million YoY, and Net loss of $65.7 million also significantly improved by $127.8 million YoY.

    Oscar is raising its full year 2023 outlook for InsuranceCo Adjusted EBITDA and consolidated Adjusted EBITDA to reflect year-to-date outperformance. The Company projects InsuranceCo Adjusted EBITDA to be in the $155 million to $165 million range, above the high-end of the prior range of $20 million to $120 million. Additionally, the Company now projects consolidated Adjusted EBITDA loss to be in the ($60) million to ($50) million range, above the high-end of the prior range of ($175) million to ($75) million.

    The Company is also announcing a new +Oscar agreement with Sanford Health Plan, a leading provider-sponsored health plan in the Midwest. The multi-year agreement leverages +Oscar's Campaign Builder technology solution to drive member engagement and interconnectivity throughout the health plan's operations.

    Financial Results Summary

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Premiums before ceded reinsurance

    $

    1,394,985

     

     

    $

    1,318,048

     

     

    $

    4,305,785

     

     

    $

    4,001,589

     

    Reinsurance premiums ceded

     

    (2,903

    )

     

     

    (364,384

    )

     

     

    (10,111

    )

     

     

    (1,097,929

    )

    Premiums earned

    $

    1,392,082

     

     

    $

    953,664

     

     

    $

    4,295,674

     

     

    $

    2,903,660

     

    Total revenue

    $

    1,439,991

     

     

    $

    978,427

     

     

    $

    4,431,211

     

     

    $

    2,968,511

     

    Total operating expenses

    $

    1,498,235

     

     

    $

    1,170,799

     

     

    $

    4,521,349

     

     

    $

    3,335,899

     

    Net loss

    $

    (65,703

    )

     

    $

    (193,547

    )

     

    $

    (120,756

    )

     

    $

    (382,992

    )

    Key Metrics and Non-GAAP Financial Metrics

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

    Direct and Assumed Policy Premiums (in thousands)

    $

    1,606,407

     

     

    $

    1,682,289

     

     

    $

    4,970,985

     

     

    $

    5,058,427

     

    Medical Loss Ratio

     

    83.8

    %

     

     

    89.9

    %

     

     

    80.0

    %

     

     

    83.2

    %

    InsuranceCo Administrative Expense Ratio

     

    17.4

    %

     

     

    20.7

    %

     

     

    17.6

    %

     

     

    20.0

    %

    InsuranceCo Combined Ratio

     

    101.3

    %

     

     

    110.6

    %

     

     

    97.6

    %

     

     

    103.2

    %

    Adjusted Administrative Expense Ratio

     

    20.3

    %

     

     

    24.8

    %

     

     

    20.5

    %

     

     

    24.1

    %

    Adjusted EBITDA(1) (in thousands)

    $

    (20,285

    )

     

    $

    (159,754

    )

     

    $

    66,355

     

     

    $

    (272,599

    )

    (1)

    Adjusted EBITDA is a non-GAAP measure. See "Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA" in this release for a reconciliation to net loss, the most directly comparable GAAP measure, and for information regarding Oscar's use of Adjusted EBITDA.

     

     

     

     

     

     

     

    As of September 30,

    Membership by Offering

     

    2023

     

    2022

    Individual and Small Group

     

    912,761

     

    1,017,544

    Medicare Advantage

     

    1,840

     

    4,577

    Cigna + Oscar (1)

     

    68,559

     

    53,324

    Total Members

     

    983,160

     

    1,075,445

    (1)

    Represents total membership for Oscar's co-branded partnership with Cigna.

    Full Year 2023 Outlook

    • Direct and Assumed Policy premiums at the high-end of the $6.4 billion - $6.6 billion range
    • Medical Loss Ratio at the low-end of the 82% - 84% range
    • InsuranceCo Administrative Expense Ratio near the midpoint of the 17% - 18% range
    • InsuranceCo Adjusted EBITDA(1) of $155 million - $165 million, above the high-end of the prior range of $20 million - $120 million
    • Adjusted Administrative Expense Ratio near the midpoint of the 20.5% - 21.5% range
    • Adjusted EBITDA(1) loss of ($60) million - ($50) million, above the high-end of the prior range of ($175) million - ($75) million

    (1)

    Please see "Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA" below.

    The foregoing statements represent management's current estimates as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

    Quarterly Conference Call Details

    Oscar will host a conference call to discuss the financial results today, November 7, 2023, at 8:00 a.m. (ET). A live audio webcast will be available via the Investor Relations page of Oscar's website at ir.hioscar.com. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    Non-GAAP Financial Information

    This release presents Adjusted EBITDA and InsuranceCo Adjusted EBITDA, non-GAAP financial metrics, which are provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America ("GAAP"). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. For more information regarding Adjusted EBITDA, please see "Key Operating and Non-GAAP Financial Metrics" below.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including direct and assumed policy premiums, medical loss ratio, administrative expense ratio, InsuranceCo Adjusted EBITDA and Adjusted EBITDA and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, and our management's plans and objectives for future operations, expectations and business strategy, including planned +Oscar partnerships. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.

    Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively; our ability to retain and expand our member base; heightened competition in the markets in which we participate; our ability to accurately estimate our incurred medical expenses or effectively manage our medical costs or related administrative costs; our ability to achieve or maintain profitability in the future; changes in federal or state laws or regulations, including changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the "ACA") and any regulations enacted thereunder; our ability to comply with ongoing regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the health insurance markets in the United States, including passage and implementation of a law to create a single-payer or government-run health insurance program; our ability to comply with applicable privacy, security, and data laws, regulations, and standards, including as a result of our participation in government-sponsored programs, such as Medicare; our ability to arrange for the delivery of quality care and maintain good relations with the physicians, hospitals, and other providers within and outside our provider networks; unanticipated results of risk adjustment programs; our ability to utilize quota share reinsurance to reduce our capital and surplus requirements and protect against downside risk on medical claims; unfavorable or otherwise costly outcomes of lawsuits and claims that arise from the extensive laws and regulations to which we are subject; our ability to attract and retain qualified personnel; incurrence of cyber-security breaches of our and our partners' information and technology systems; our ability to remediate a material weakness in our internal controls over financial reporting and the identification of additional material weaknesses in the future or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or "controlled company" status; and the other factors set forth under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, filed with the Securities and Exchange Commission ("SEC"), and our other filings with the SEC, including our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, to be filed with the SEC.

    You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

    About Oscar Health

    Oscar Health, Inc. ("Oscar") is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the health care system's status quo since our founding in 2012. The company's member-first philosophy and innovative approach to care has earned us the trust of nearly one million members, as of September 30, 2023. We offer Individual & Family, Small Group and Medicare Advantage plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members' experience by building trust through deep engagement, personalized guidance, and rapid iteration.

    Oscar Health, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share amounts)

    (unaudited)

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

    Revenue

     

     

     

     

     

     

     

    Premiums before ceded reinsurance

    $

    1,394,985

     

     

    $

    1,318,048

     

     

    $

    4,305,785

     

     

    $

    4,001,589

     

    Reinsurance premiums ceded

     

    (2,903

    )

     

     

    (364,384

    )

     

     

    (10,111

    )

     

     

    (1,097,929

    )

    Premiums earned

     

    1,392,082

     

     

     

    953,664

     

     

     

    4,295,674

     

     

     

    2,903,660

     

    Administrative services revenue

     

    3,871

     

     

     

    19,421

     

     

     

    11,612

     

     

     

    58,366

     

    Investment income and other revenue

     

    44,038

     

     

     

    5,342

     

     

     

    123,925

     

     

     

    6,485

     

    Total revenue

     

    1,439,991

     

     

     

    978,427

     

     

     

    4,431,211

     

     

     

    2,968,511

     

     

     

     

     

     

     

     

     

    Operating Expenses

     

     

     

     

     

     

     

    Claims incurred, net

     

    1,163,194

     

     

     

    852,689

     

     

     

    3,436,785

     

     

     

    2,395,894

     

    Other insurance costs

     

    192,863

     

     

     

    174,978

     

     

     

    618,078

     

     

     

    510,580

     

    General and administrative expenses

     

    75,503

     

     

     

    78,557

     

     

     

    254,106

     

     

     

    233,975

     

    Federal and state assessments

     

    69,876

     

     

     

    71,114

     

     

     

    216,414

     

     

     

    209,730

     

    Premium deficiency reserve release

     

    (3,201

    )

     

     

    (6,539

    )

     

     

    (4,034

    )

     

     

    (14,280

    )

    Total operating expenses

     

    1,498,235

     

     

     

    1,170,799

     

     

     

    4,521,349

     

     

     

    3,335,899

     

    Loss from operations

     

    (58,244

    )

     

     

    (192,372

    )

     

     

    (90,138

    )

     

     

    (367,388

    )

    Interest expense

     

    6,130

     

     

     

    6,126

     

     

     

    18,386

     

     

     

    16,488

     

    Other expenses (income)

     

    414

     

     

     

    (3,336

    )

     

     

    8,132

     

     

     

    (1,076

    )

    Loss before income taxes

     

    (64,788

    )

     

     

    (195,162

    )

     

     

    (116,656

    )

     

     

    (382,800

    )

    Income tax expense (benefit)

     

    915

     

     

     

    (1,615

    )

     

     

    4,100

     

     

     

    192

     

    Net loss

     

    (65,703

    )

     

     

    (193,547

    )

     

     

    (120,756

    )

     

     

    (382,992

    )

    Less: Net income (loss) attributable to noncontrolling interests

     

    (305

    )

     

     

    (634

    )

     

     

    (58

    )

     

     

    (2,763

    )

    Net loss attributable to Oscar Health, Inc.

    $

    (65,398

    )

     

    $

    (192,913

    )

     

    $

    (120,698

    )

     

    $

    (380,229

    )

     

     

     

     

     

     

     

     

    Earnings (Loss) per Share

     

     

     

     

     

     

     

    Net loss per share attributable to Oscar Health, Inc., basic and diluted

    $

    (0.29

    )

     

    $

    (0.91

    )

     

    $

    (0.55

    )

     

    $

    (1.80

    )

    Weighted average common shares outstanding, basic and diluted

     

    223,098,974

     

     

     

    212,822,733

     

     

     

    219,826,759

     

     

     

    211,560,332

     

     

    Oscar Health, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share amounts)

    (unaudited)

     

     

    September 30, 2023

     

    December 31, 2022

    Assets

     

     

     

    Current Assets:

     

     

     

    Cash and cash equivalents

    $

    1,399,791

     

     

    $

    1,558,595

     

    Short-term investments

     

    1,044,445

     

     

     

    1,397,287

     

    Premiums and accounts receivable

     

    207,098

     

     

     

    216,475

     

    Risk adjustment transfer receivable

     

    54,127

     

     

     

    49,861

     

    Reinsurance recoverable

     

    277,803

     

     

     

    892,887

     

    Other current assets

     

    8,358

     

     

     

    6,450

     

    Total current assets

     

    2,991,622

     

     

     

    4,121,555

     

    Property, equipment, and capitalized software, net

     

    62,022

     

     

     

    59,888

     

    Long-term investments

     

    179,633

     

     

     

    222,919

     

    Restricted deposits

     

    27,335

     

     

     

    27,483

     

    Other assets

     

    88,899

     

     

     

    94,756

     

    Total Assets

    $

    3,349,511

     

     

    $

    4,526,601

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current Liabilities:

     

     

     

    Benefits payable

    $

    910,449

     

     

    $

    937,727

     

    Risk adjustment transfer payable

     

    751,196

     

     

     

    1,517,493

     

    Premium deficiency reserve

     

    179

     

     

     

    4,214

     

    Unearned premiums

     

    71,601

     

     

     

    78,998

     

    Accounts payable and other liabilities

     

    260,137

     

     

     

    297,841

     

    Reinsurance payable

     

    67,314

     

     

     

    427,649

     

    Total current liabilities

     

    2,060,876

     

     

     

    3,263,922

     

    Long-term debt

     

    298,583

     

     

     

    297,999

     

    Other liabilities

     

    68,618

     

     

     

    72,280

     

    Total liabilities

     

    2,428,077

     

     

     

    3,634,201

     

    Commitments and contingencies

     

     

     

    Stockholders' Equity

     

     

     

    Preferred stock, $0.00001 par value; 82,500,000 shares authorized, none outstanding as of September 30, 2023 and December 31, 2022

     

    —

     

     

     

    —

     

    Class A common stock, $0.00001 par value; 825,000,000 shares authorized, 190,796,321 and 181,176,239 shares outstanding as of September 30, 2023 and December 31, 2022, respectively

     

    2

     

     

     

    2

     

    Class B common stock, $0.00001 par value; 82,500,000 shares authorized, 35,296,176 and 35,115,807 shares outstanding as of September 30, 2023 and December 31, 2022, respectively

     

    —

     

     

     

    —

     

    Treasury stock (314,600 shares as of September 30, 2023 and December 31, 2022)

     

    (2,923

    )

     

     

    (2,923

    )

    Additional paid-in capital

     

    3,653,535

     

     

     

    3,509,007

     

    Accumulated deficit

     

    (2,726,685

    )

     

     

    (2,605,987

    )

    Accumulated other comprehensive income (loss)

     

    (4,453

    )

     

     

    (9,715

    )

    Total Oscar Health, Inc. stockholders' equity

     

    919,476

     

     

     

    890,384

     

    Noncontrolling interests

     

    1,958

     

     

     

    2,016

     

    Total stockholders' equity

     

    921,434

     

     

     

    892,400

     

    Total Liabilities and Stockholders' Equity

    $

    3,349,511

     

     

    $

    4,526,601

     

     

    Oscar Health, Inc.

    Condensed Consolidated Statements of Cash Flows

    (in thousands) (unaudited)

     

     

    Nine Months Ended September 30,

     

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (120,756

    )

     

    $

    (382,992

    )

    Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

     

     

     

    Deferred taxes

     

    95

     

     

     

    6

     

    Net realized loss on sale of financial instruments

     

    70

     

     

     

    1,269

     

    Depreciation and amortization expense

     

    22,952

     

     

     

    11,548

     

    Amortization of debt issuance costs

     

    583

     

     

     

    519

     

    Stock-based compensation expense

     

    133,541

     

     

     

    83,241

     

    Net amortization (accretion) of investments

     

    (22,856

    )

     

     

    4,138

     

    Changes in assets and liabilities:

     

     

     

    (Increase) / decrease in:

     

     

     

    Premiums and accounts receivable

     

    9,378

     

     

     

    (77,057

    )

    Risk adjustment transfer receivable

     

    (4,265

    )

     

     

    (3,597

    )

    Reinsurance recoverable

     

    615,084

     

     

     

    (392,488

    )

    Other assets

     

    3,854

     

     

     

    (12,159

    )

    Increase / (decrease) in:

     

     

     

    Benefits payable

     

    (27,278

    )

     

     

    482,178

     

    Unearned premiums

     

    (7,396

    )

     

     

    90

     

    Premium deficiency reserve

     

    (4,035

    )

     

     

    (14,280

    )

    Accounts payable and other liabilities

     

    (41,366

    )

     

     

    13,842

     

    Reinsurance payable

     

    (360,335

    )

     

     

    230,401

     

    Risk adjustment transfer payable

     

    (766,297

    )

     

     

    284,296

     

    Net cash (used in) provided by operating activities

     

    (569,027

    )

     

     

    228,955

     

    Cash flows from investing activities:

     

     

     

    Purchase of investments

     

    (622,183

    )

     

     

    (343,178

    )

    Sale of investments

     

    26,656

     

     

     

    360,449

     

    Maturity of investments

     

    1,019,612

     

     

     

    483,224

     

    Purchase of property, equipment and capitalized software

     

    (19,475

    )

     

     

    (21,882

    )

    Change in restricted deposits

     

    100

     

     

     

    1,548

     

    Net cash provided by investing activities

     

    404,710

     

     

     

    480,161

     

    Cash flows from financing activities:

     

     

     

    Proceeds from long-term debt

     

    —

     

     

     

    305,000

     

    Payments of debt issuance costs

     

    —

     

     

     

    (7,035

    )

    Proceeds from joint venture contribution

     

    2,491

     

     

     

    1,324

     

    Proceeds from exercise of stock options

     

    2,886

     

     

     

    1,294

     

    Net cash provided by financing activities

     

    5,377

     

     

     

    300,583

     

    Increase (decrease) in cash, cash equivalents and restricted cash equivalents

     

    (158,940

    )

     

     

    1,009,699

     

    Cash, cash equivalents, restricted cash and cash equivalents—beginning of period

     

    1,580,497

     

     

     

    1,125,557

     

    Cash, cash equivalents, restricted cash and cash equivalents—end of period

     

    1,421,557

     

     

     

    2,135,256

     

    Cash and cash equivalents

     

    1,399,791

     

     

     

    2,112,930

     

    Restricted cash and cash equivalents included in restricted deposits

     

    21,766

     

     

     

    22,326

     

    Total cash, cash equivalents and restricted cash and cash equivalents

    $

    1,421,557

     

     

    $

    2,135,256

     

     

     

    Nine Months Ended September 30,

     

    2023

     

    2022

    Supplemental Disclosures:

     

     

     

    Interest payments

    $

    22,893

     

    $

    9,810

    Income tax payments

    $

    1,000

     

    $

    1,660

    Key Operating and Non-GAAP Financial Metrics

    We regularly review a number of metrics, including the following key operating and non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.

    Members

    Members are defined as any individual covered by a health plan that we offer directly or through a co-branded arrangement. We view the number of members enrolled in our health plans as an important metric to help evaluate and estimate revenue and market share. Additionally, the more members we enroll, the more data we have, which allows us to improve the functionality of our platform.

    Direct and Assumed Policy Premiums

    Direct Policy Premiums are defined as the premiums collected from our members or from the federal government during the period indicated, before risk adjustment and reinsurance. These premiums include APTC, or premium subsidies, which are available to individuals and families with certain annual incomes.

    Assumed Policy Premiums are premiums we receive primarily as part of our reinsurance arrangement under our Cigna+Oscar Small Group plan offering, and are presented here net of Risk Adjustment.

    We believe Direct and Assumed Policy Premiums is an important metric to assess the growth of our individual and small group plan offerings going forward. Management also views Direct and Assumed Policy Premiums as a key operating metric because each of our MLR, InsuranceCo Administrative Expense Ratio, InsuranceCo Combined Ratio and Adjusted Administrative Expense Ratio are calculated on the basis of Direct and Assumed Policy Premiums.

    Medical Loss Ratio

    Medical Loss Ratio is calculated as set forth in the table below. Medical claims are total medical expenses incurred by members in order to utilize health care services less any member cost sharing. These services include inpatient, outpatient, pharmacy, and physician costs. Medical claims also include risk sharing arrangements with certain of our providers. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for health care of our members to the premiums before ceded reinsurance. MLRs in our existing products are subject to various federal and state minimum requirements. Below is a calculation of our MLR for the periods indicated.

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Direct claims incurred before ceded reinsurance (1)

    $

    1,116,679

     

     

    $

    1,153,270

     

     

    $

    3,301,424

     

     

    $

    3,255,721

     

    Assumed reinsurance claims

     

    61,781

     

     

     

    38,667

     

     

     

    169,194

     

     

     

    95,464

     

    Excess of loss ceded claims (2)

     

    (418

    )

     

     

    (4,392

    )

     

     

    (6,038

    )

     

     

    (14,316

    )

    State reinsurance (3)

     

    (9,978

    )

     

     

    (10,368

    )

     

     

    (26,574

    )

     

     

    (28,643

    )

    Net claims before ceded quota share reinsurance (A)

    $

    1,168,064

     

     

    $

    1,177,177

     

     

    $

    3,438,006

     

     

    $

    3,308,226

     

     

     

     

     

     

     

     

     

    Premiums before ceded reinsurance

    $

    1,394,985

     

     

    $

    1,318,048

     

     

    $

    4,305,785

     

     

    $

    4,001,589

     

    Excess of loss reinsurance premiums (4)

     

    (1,457

    )

     

     

    (8,621

    )

     

     

    (7,981

    )

     

     

    (23,387

    )

    Net premiums before ceded quota share reinsurance (B)

    $

    1,393,528

     

     

    $

    1,309,427

     

     

    $

    4,297,804

     

     

    $

    3,978,202

     

    Medical Loss Ratio (A divided by B)

     

    83.8

    %

     

     

    89.9

    %

     

     

    80.0

    %

     

     

    83.2

    %

    (1)

    See the Appendix to this release for a reconciliation of direct claims incurred to claims incurred, net appearing on the face of our statement of operations.

    (2)

    Represents claims ceded to reinsurers pursuant to an excess of loss treaty, for which such reinsurers are financially liable. We use excess of loss reinsurance to limit the losses on individual claims of our members.

    (3)

    Represents payments made by certain state-run reinsurance programs established subject to CMS approval under Section 1332 of the ACA.

    (4)

    Represents excess of loss insurance premiums paid.

    InsuranceCo Administrative Expense Ratio

    InsuranceCo Administrative Expense Ratio is calculated as set forth in the table below. The ratio reflects the costs associated with running our combined insurance companies. We believe InsuranceCo Administrative Expense Ratio is useful to evaluate our ability to manage our expenses as a percentage of premiums before the impact of quota share reinsurance. Expenses necessary to run the insurance companies are included in other insurance costs and federal and state assessments. These expenses include variable expenses paid to vendors and distribution partners, premium taxes and healthcare exchange fees, employee-related compensation, benefits, marketing costs, and other administrative expenses. The numerator and denominator in the calculation below reflect an adjustment to remove the impact of the Company's quota share arrangements. Below is a calculation of our InsuranceCo Administrative Expense Ratio for the periods indicated.

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Other insurance costs

    $

    192,863

     

     

    $

    174,978

     

     

    $

    618,078

     

     

    $

    510,580

     

    Impact of quota share reinsurance (1)

     

    (7,169

    )

     

     

    38,328

     

     

     

    (23,431

    )

     

     

    113,996

     

    Stock-based compensation expense

     

    (12,811

    )

     

     

    (12,963

    )

     

     

    (54,602

    )

     

     

    (38,452

    )

    Federal and state assessment of health insurance subsidiaries

     

    70,252

     

     

     

    70,806

     

     

     

    215,732

     

     

     

    209,578

     

    Health insurance subsidiary adjusted administrative expenses(A)

    $

    243,135

     

     

    $

    271,149

     

     

    $

    755,777

     

     

    $

    795,702

     

     

     

     

     

     

     

     

     

    Premiums before ceded reinsurance

    $

    1,394,985

     

     

    $

    1,318,048

     

     

    $

    4,305,785

     

     

    $

    4,001,589

     

    Excess of loss reinsurance premiums

     

    (1,457

    )

     

     

    (8,621

    )

     

     

    (7,981

    )

     

     

    (23,387

    )

    Net premiums before ceded quota share reinsurance(B)

    $

    1,393,528

     

     

    $

    1,309,427

     

     

    $

    4,297,804

     

     

    $

    3,978,202

     

    InsuranceCo Administrative Expense Ratio(A divided by B)

     

    17.4

    %

     

     

    20.7

    %

     

     

    17.6

    %

     

     

    20.0

    %

    (1)

    Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(7,139) and $(1,758) for the three months ended September 30, 2023 and 2022, respectively, and $(22,455) and $(5,417) for the nine months ended September 30, 2023 and 2022, respectively.

    InsuranceCo Combined Ratio

    InsuranceCo Combined Ratio is defined as the sum of MLR and InsuranceCo Administrative Expense Ratio. We believe this ratio best represents the core performance of the insurance business, prior to the impact of quota share and net investment income.

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

    Medical Loss Ratio

    83.8

    %

     

    89.9

    %

     

    80.0

    %

     

    83.2

    %

    InsuranceCo Administrative Expense Ratio

    17.4

    %

     

    20.7

    %

     

    17.6

    %

     

    20.0

    %

    InsuranceCo Combined Ratio

    101.3

    %

     

    110.6

    %

     

    97.6

    %

     

    103.2

    %

    Adjusted Administrative Expense Ratio

    The Adjusted Administrative Expense Ratio is an operating ratio that reflects the Company's total administrative expenses ("Total Administrative Expenses"), net of non-cash and non-recurring items (as adjusted, "Adjusted Administrative Expenses"), as a percentage of total revenue, including quota share reinsurance premiums ceded and excluding excess of loss reinsurance premiums ceded and non-recurring items ("Adjusted Total Revenue"). Total Administrative Expenses are calculated as Total Operating Expenses, excluding non-administrative insurance-based expenses and the impact of quota share reinsurance. Adjusted Administrative Expenses are Total Administrative Expenses, net of non-cash and non-recurring expense items. Adjusted Administrative Expenses exclude insurance-based expenses, non-cash expenses and non-recurring expenses. The Company believes Adjusted Administrative Expense Ratio is useful to evaluate the Company's ability to manage its overall administrative expense base. This ratio also provides further clarity into the Company's overall path to profitability. Below is a calculation of our Adjusted Administrative Expense Ratio for the periods indicated.

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Total Operating Expenses

    $

    1,498,235

     

     

    $

    1,170,799

     

     

    $

    4,521,349

     

     

    $

    3,335,899

     

    Claims incurred, net

     

    (1,163,194

    )

     

     

    (852,689

    )

     

     

    (3,436,785

    )

     

     

    (2,395,894

    )

    Premium deficiency reserve release

     

    3,201

     

     

     

    6,539

     

     

     

    4,034

     

     

     

    14,280

     

    Impact of quota share reinsurance (1)

     

    (7,169

    )

     

     

    38,328

     

     

     

    (23,431

    )

     

     

    113,996

     

    Total Administrative Expenses

    $

    331,073

     

     

    $

    362,977

     

     

    $

    1,065,167

     

     

    $

    1,068,281

     

    Stock-based compensation expense

     

    (28,768

    )

     

     

    (28,560

    )

     

     

    (133,541

    )

     

     

    (83,241

    )

    Depreciation and amortization

     

    (9,191

    )

     

     

    (4,058

    )

     

     

    (22,952

    )

     

     

    (11,548

    )

    Adjusted Administrative Expenses (A)

    $

    293,114

     

     

    $

    330,359

     

     

    $

    908,674

     

     

    $

    973,492

     

    Total Revenue

    $

    1,439,991

     

     

    $

    978,427

     

     

    $

    4,431,211

     

     

    $

    2,968,511

     

    Reinsurance premiums ceded

     

    2,903

     

     

     

    364,384

     

     

     

    10,111

     

     

     

    1,097,929

     

    Excess of loss reinsurance premiums

     

    (1,457

    )

     

     

    (8,621

    )

     

     

    (7,981

    )

     

     

    (23,387

    )

    Adjusted Total Revenue (B)

    $

    1,441,437

     

     

    $

    1,334,190

     

     

    $

    4,433,341

     

     

    $

    4,043,053

     

    Adjusted Administrative Expense Ratio (A divided by B)

     

    20.3

    %

     

     

    24.8

    %

     

     

    20.5

    %

     

     

    24.1

    %

    (1)

    Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(7,139) and $(1,758) for the three months ended September 30, 2023 and 2022, respectively, and $(22,455) and $(5,417) for the nine months ended September 30, 2023 and 2022, respectively.

    Adjusted EBITDA

    Adjusted EBITDA is defined as net loss for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), depreciation and amortization as further adjusted for stock-based compensation, and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors' understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

    We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.

    Management uses Adjusted EBITDA:

    • as a measurement of operating performance because it assists us in comparing the operating performance of our business on a consistent basis, as it removes the impact of items not directly resulting from our core operations;
    • for planning purposes, including the preparation of our internal annual operating budget and financial projections;
    • to evaluate the performance and effectiveness of our operational strategies; and
    • to evaluate our capacity to expand our business.

    By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net loss, we believe we are enhancing investors' understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for Net loss or other financial statement data presented in our Condensed Consolidated Financial Statements as indicators of financial performance.

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Net loss

    $

    (65,703

    )

     

    $

    (193,547

    )

     

    $

    (120,756

    )

     

    $

    (382,992

    )

    Interest expense

     

    6,130

     

     

     

    6,126

     

     

     

    18,386

     

     

     

    16,488

     

    Other expenses (income)

     

    414

     

     

     

    (3,336

    )

     

     

    8,132

     

     

     

    (1,076

    )

    Income tax expense (benefit)

     

    915

     

     

     

    (1,615

    )

     

     

    4,100

     

     

     

    192

     

    Depreciation and amortization ("D&A")

     

    9,191

     

     

     

    4,058

     

     

     

    22,952

     

     

     

    11,548

     

    Stock-based compensation ("SBC")(1)

     

    28,768

     

     

     

    28,560

     

     

     

    133,541

     

     

     

    83,241

     

    Adjusted EBITDA

    $

    (20,285

    )

     

    $

    (159,754

    )

     

    $

    66,355

     

     

    $

    (272,599

    )

     

     

     

     

     

     

     

     

    General and administrative expenses (excluding SBC and D&A)

     

    58,407

     

     

     

    62,413

     

     

     

    173,579

     

     

     

    187,394

     

    Administrative services revenue

     

    (3,871

    )

     

     

    (19,421

    )

     

     

    (11,612

    )

     

     

    (58,366

    )

    Investment income and other revenue (Non-InsuranceCo)

     

    (4,214

    )

     

     

    (1,269

    )

     

     

    (9,936

    )

     

     

    (3,684

    )

    InsuranceCo Adjusted EBITDA(2)

    $

    30,037

     

     

    $

    (118,031

    )

     

    $

    218,386

     

     

    $

    (147,255

    )

    (1)

    Represents non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number, and the valuation of awards. Nine months ended September 30, 2023, includes a non-recurring charge of $46.3 million related to accelerated stock-based compensation expense recognized as a result of the cancellation of the Founders Awards previously granted to Mario Schlosser and Joshua Kushner.

    (2)

    We believe that InsuranceCo Adjusted EBITDA provides investors with additional insight into the earnings and capital generation potential of the Company's insurance subsidiaries.

    The Company has not provided a quantitative reconciliation of forecasted InsuranceCo Adjusted EBITDA and Adjusted EBITDA to the appropriate forecasted GAAP metric within this press release because the Company is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items, which could materially affect the computation of forecasted GAAP net loss, are inherently uncertain and depend on various factors, some of which are outside of the Company's control. As such, any associated estimate and its impact on GAAP net loss could vary materially.

    Appendix

    Reinsurance Impact

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Quota share ceded premiums

    $

    284

     

     

    $

    (374,092

    )

     

    $

    7,107

     

     

    $

    (1,117,357

    )

    Quota share ceded claims

     

    4,869

     

     

     

    324,487

     

     

     

    1,221

     

     

     

    912,332

     

    Ceding commission, net of deposit accounting impact (1)

     

    (7,169

    )

     

     

    38,328

     

     

     

    (23,431

    )

     

     

    113,996

     

    Experience refund

     

    (1,732

    )

     

     

    18,330

     

     

     

    (9,238

    )

     

     

    42,816

     

    Net quota share impact

    $

    (3,748

    )

     

    $

    7,053

     

     

    $

    (24,341

    )

     

    $

    (48,213

    )

    (1)

    Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(7,139) and $(1,758) for the three months ended September 30, 2023 and 2022, respectively, and $(22,455) and $(5,417) for the nine months ended September 30, 2023 and 2022, respectively.

    The composition of total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total earned premiums in the condensed consolidated statement of operations, is as follows:

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Reinsurance premiums ceded, gross

    $

    (1,354

    )

     

    $

    (382,597

    )

     

    $

    1,514

     

     

    $

    (1,143,565

    )

    Experience refunds

     

    (1,549

    )

     

     

    18,213

     

     

     

    (11,625

    )

     

     

    45,636

     

    Reinsurance premiums ceded

     

    (2,903

    )

     

     

    (364,384

    )

     

     

    (10,111

    )

     

     

    (1,097,929

    )

    Reinsurance premiums assumed

     

    57,836

     

     

     

    37,409

     

     

     

    174,166

     

     

     

    96,294

     

    Total reinsurance premiums (ceded) and assumed

    $

    54,933

     

     

    $

    (326,975

    )

     

    $

    164,055

     

     

    $

    (1,001,635

    )

    The Company records claims expense net of reinsurance recoveries. The following table reconciles the total claims expense to the net claims expense as presented in the condensed consolidated statement of operations:

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Direct claims incurred

    $

    1,116,679

     

     

    $

    1,153,270

     

     

    $

    3,301,424

     

     

    $

    3,255,721

     

    Ceded reinsurance claims

     

    (15,266

    )

     

     

    (339,248

    )

     

     

    (33,833

    )

     

     

    (955,291

    )

    Assumed reinsurance claims

     

    61,781

     

     

     

    38,667

     

     

     

    169,194

     

     

     

    95,464

     

    Claims incurred, net

    $

    1,163,194

     

     

    $

    852,689

     

     

    $

    3,436,785

     

     

    $

    2,395,894

     

    The Company records general and administrative expenses net of ceding commissions. The following table reconciles total other insurance costs to the amount presented in the condensed consolidated statement of operations:

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in thousands)

    Other insurance costs, gross

    $

    192,833

     

    $

    215,064

     

     

    $

    617,102

     

    $

    629,993

     

    Reinsurance ceding commissions

     

    30

     

     

    (40,086

    )

     

     

    976

     

     

    (119,413

    )

    Other insurance costs

    $

    192,863

     

    $

    174,978

     

     

    $

    618,078

     

    $

    510,580

     

    The Company records reinsurance recoverables within current assets on its condensed consolidated balance sheets. The composition of the reinsurance recoverable balance is as follows:

     

     

    September 30, 2023

     

    December 31, 2022

     

     

    (in thousands)

    Ceded reinsurance claim recoverables

     

    $

    255,754

     

    $

    776,266

    Reinsurance ceding commissions

     

     

    15,248

     

     

    42,805

    Experience refunds on reinsurance agreements

     

     

    6,801

     

     

    73,816

    Reinsurance recoverable

     

    $

    277,803

     

    $

    892,887

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231107462034/en/

    Get the next $OSCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    2/12/2026$18.00Mkt Perform → Outperform
    Raymond James
    1/9/2026$17.00Sell → Neutral
    UBS
    1/5/2026$18.00Underweight → Equal Weight
    Barclays
    12/11/2025$17.00Equal-Weight
    Stephens
    11/26/2025$25.00Neutral → Overweight
    Piper Sandler
    10/14/2025$17.00Neutral
    Goldman
    7/25/2025$14.00Outperform → Neutral
    Robert W. Baird
    7/15/2025$11.00Neutral → Sell
    UBS
    More analyst ratings

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oscar Health, Inc. 2026 First Quarter Earnings Conference Call

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2026 financial results before the market opens on Wednesday, May 6, 2026. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 6, 2026 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentl

    4/7/26 8:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

    DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill' Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the "Board") effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. His appointment expands the Board to 10 directors, eight of whom are independent. "Bill brings deep insight into how care is delivered, how it is financed

    3/30/26 8:30:00 AM ET
    $HQY
    $OSCR
    Real Estate
    Medical Specialities
    Health Care

    Oscar Health Announces Financial Results for Fourth Quarter and Full-Year 2025

    Achieves Record Membership of ~3.4 Million and Provides Full-Year 2026 Outlook Including More Than $18 Billion in Revenue Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a reset year for the individual market, and we took decisive actions to return to profitability in 2026," said Mark Bertolini, CEO of Oscar Health. "Our new suite of affordable products, agentic AI features, and exceptional member experience drove record-high membership – positioning us to achieve significantly improved financial performance in 2026. Oscar's growth demonstrates consumers vote where the

    2/10/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Oscar Health Inc.

    SCHEDULE 13G/A - Oscar Health, Inc. (0001568651) (Subject)

    3/27/26 11:06:35 AM ET
    $OSCR
    Medical Specialities
    Health Care

    SEC Form 144 filed by Oscar Health Inc.

    144 - Oscar Health, Inc. (0001568651) (Subject)

    3/2/26 4:17:41 PM ET
    $OSCR
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Oscar Health Inc.

    8-K - Oscar Health, Inc. (0001568651) (Filer)

    3/2/26 6:41:46 AM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oscar Health upgraded by Raymond James with a new price target

    Raymond James upgraded Oscar Health from Mkt Perform to Outperform and set a new price target of $18.00

    2/12/26 7:19:33 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health upgraded by UBS with a new price target

    UBS upgraded Oscar Health from Sell to Neutral and set a new price target of $17.00

    1/9/26 8:33:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health upgraded by Barclays with a new price target

    Barclays upgraded Oscar Health from Underweight to Equal Weight and set a new price target of $18.00

    1/5/26 8:36:06 AM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bertolini Mark T

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    4/7/26 4:16:39 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Chief Financial Officer Blackley Richard Scott received a gift of 75,000 shares and gifted 150,000 shares, decreasing direct ownership by 10% to 1,316,660 units (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    3/16/26 4:24:25 PM ET
    $OSCR
    Medical Specialities
    Health Care

    President, Oscar Insurance Liang Janet was granted 106,458 shares and sold $99,796 worth of shares (7,453 units at $13.39), increasing direct ownership by 57% to 271,532 units (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    3/4/26 4:23:39 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    11/22/24 4:33:02 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    11/22/24 4:29:47 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    11/18/24 5:02:12 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

    SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

    11/14/24 4:07:27 PM ET
    $OSCR
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Oscar Health Inc.

    SC 13G - Oscar Health, Inc. (0001568651) (Subject)

    11/14/24 1:28:35 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

    SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

    11/13/24 9:24:55 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Financials

    Live finance-specific insights

    View All

    Oscar Health, Inc. 2026 First Quarter Earnings Conference Call

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2026 financial results before the market opens on Wednesday, May 6, 2026. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 6, 2026 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentl

    4/7/26 8:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health Announces Financial Results for Fourth Quarter and Full-Year 2025

    Achieves Record Membership of ~3.4 Million and Provides Full-Year 2026 Outlook Including More Than $18 Billion in Revenue Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a reset year for the individual market, and we took decisive actions to return to profitability in 2026," said Mark Bertolini, CEO of Oscar Health. "Our new suite of affordable products, agentic AI features, and exceptional member experience drove record-high membership – positioning us to achieve significantly improved financial performance in 2026. Oscar's growth demonstrates consumers vote where the

    2/10/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its fourth quarter and full year 2025 financial results before the market opens on Tuesday, February 10, 2026. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following February 10, 2026 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack techno

    1/13/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    View All

    HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

    DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill' Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the "Board") effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. His appointment expands the Board to 10 directors, eight of whom are independent. "Bill brings deep insight into how care is delivered, how it is financed

    3/30/26 8:30:00 AM ET
    $HQY
    $OSCR
    Real Estate
    Medical Specialities
    Health Care

    Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

    Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

    1/26/24 8:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

    Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

    9/6/23 8:30:00 AM ET
    $OSCR
    Medical Specialities
    Health Care